CSGA

CSGA Protein

Score: 0.422 Price: $0.42 Medium Druggability Status: active
HYPOTHESES
1
PAPERS
11
KG EDGES
0
DEBATES
1

Druggability & Clinical Context

Druggability
Medium
Score: 0.50
Clinical Stage
Phase I
Target Class
Protein
Safety
0.50
Druggability Analysis
Drug Development0.00
Structural Tractability0.30
Target Class0.50
Safety Profile0.50
Key Metrics
PDB Structures:
0
Known Drugs:
0
Approved:
0
In Clinical Trials:
0
Mechanism: Prioritized from 1 SciDEX hypotheses, including: Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding
Known Drugs:
No known drugs targeting this protein
Structural Data:

Linked Hypotheses (1)

Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding0.642

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Portfolio 0.00 (25%) Druggability 0.50 (20%) Evidence 0.79 (20%) Safety 0.50 (15%) Competitive 0.90 (10%) Connectivity 0.00 (10%) 0.422 composite

Knowledge Graph (20)

activates (2)

APPCSGACSGAAPP

associated with (2)

CSGAneurodegenerationCSGARb

co discussed (6)

TDCCSGATLR4CSGADDCCSGAGPR109ACSGACHRNA7CSGA
▸ Show 1 more
AGERCSGA

contributes to (1)

CSGAbiofilm formation

debate co mention (3)

AADCCSGACSGAGPR109ACSGAneuroinflammation

expressed in (1)

CSGAgut microbiome

inhibits (1)

fibrinogenCSGA

interacts with (3)

CSGAamyloid betaCSGAcontact-phase proteinsCSGARb

modulates (1)

CSGAinnate immune system

Debate History (1)

Should CSGA (CSGA Protein) be prioritized as a therapeutic target for neurodegen2026-04-22